Delivery Order SPE2DB20D1100-SPE2DB24FC8M2

Award Date 7/22/24
Potential Completion Date 7/23/24
Potential Value $1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Entecavir 0.5 mg tablets, a medication used to treat chronic hepatitis B. The contract has a total ceiling value of $1,440.42 and a period of performance through May 14, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Entecavir 0.5 mg tablets. The order has a ceiling value of $6,918.52 and a completion date of August 5, 2024. This delivery order is likely part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $1,532.79 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the provision of 4,564,150,864 units of the prescription medication Entecavir 0.5 mg tablets. This delivery order is a part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen Drug Corp holds with DLA. The IDC serves as the primary contract vehicle for...
This is a $8,039.09 delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of ENTECAVIR 0.5 MG TABLET 30S, a medication, with a completion date of June 13, 2025. It is a firm fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 0.5 mg entecavir tablets. The $8,072.27 fixed-price contract was issued by the Defense Logistics Agency (DLA) and has a performance period through July 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA valued at up to $999,999,999 through December 2025 for providing a wide range of medical commodities to support military treatment programs...
This federal contract award, valued at $6,501.23, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Entecavir 0.5 mg tablets, a medication used to treat chronic hepatitis B. The award is a Firm Fixed Price Delivery Order and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,933.68 firm-fixed-price delivery order is for the supply of Entecavir 0.5mg tablets, a medication used to treat chronic hepatitis B infection. The contract has an ultimate completion date of August 26, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop...
This is a delivery order federal contract award valued at $22,228.26, granted by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, which has a ceiling value of $22,228.26 and a performance period through December 5, 2024, is for the supply of Entecavir 0.5 mg tablets. This contract does not have a set-aside designation, indicating open competition. AmerisourceBergen, the prime contractor, has established Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Entecavir 0.5 mg tablets, a medication used to treat hepatitis B. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $2,328.80 and a period of performance through April 18, 2025. This contract is not designated as a set-aside and was open to full and open...
This federal contract award is for the delivery of Entecavir 0.5 mg tablets to the Defense Logistics Agency (DLA). The $1,017.63 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of August 24, 2023. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB24FC8M2
    Delivery Order

This is a delivery order under a larger Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,015.95 firm fixed-price contract is for the supply of Entecavir 0.5 mg tablets, a medication used to treat chronic hepatitis B. This delivery order is part of a larger $999,999,999 IDC with DLA Troop Support Medical that runs through December 2025, enabling the government to efficiently procure a comprehensive range of pharmaceutical and medical supplies to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation.

Generated 10/21/24, 9:21 AM